- Xeris Biopharma Holdings (XERS, Financial) outlines ambitious growth strategy at 2025 Analyst & Investor Day.
- The company projects revenue of $260-$275 million in 2025, with plans to hit approximately $750 million by 2030.
- Recorlev® and XP-8121 are expected to be significant revenue drivers, with XP-8121 potentially generating $1-$3 billion by 2035.
Xeris Biopharma Holdings, Inc. (XERS), a leading biopharmaceutical company, revealed its strategic roadmap for sustainable growth and long-term value creation during its inaugural Analyst & Investor Day in New York City. The company is focusing on expanding its portfolio and capitalizing on innovative therapies to propel its financial growth trajectory.
Key to its strategy is the strong performance of Recorlev®, a product designed to treat endogenous Cushing’s syndrome, which is expected to lead future revenue growth. The company aims for total revenue in the range of $260 to $275 million by 2025, maintaining a commitment to remain adjusted EBITDA positive.
Looking further ahead, Xeris projects its total revenue will reach approximately $750 million by 2030, with Recorlev® playing a critical role. By 2035, Xeris anticipates Recorlev® will generate annual net revenue of around $1 billion, while XP-8121, an innovative treatment for hypothyroidism, can potentially bring in $1 to $3 billion in peak net revenue.
John Shannon, CEO of Xeris, emphasized the company's dedication to leveraging its capabilities and building on past successes to enhance patient care through groundbreaking medical solutions. The company’s robust financial position facilitates self-funding for both immediate and future growth efforts, ensuring that Xeris can continue to execute its ambitious plans effectively.
The event, which was accessible both in-person and online, provided investors and analysts a comprehensive overview of Xeris’ vision and strategic direction, underscoring its commitment to innovation and patient-centric solutions.
